Pipeline / Targeted Indication / Pulmonary Hypertension (PH) WHO Group 1 (PAH)

Pre-filled system for subcutaneous administration of Remodulin® (treprostinil).

Implantable System for intravenous delivery of Remodulin® (treprostinil).

*FDA requires that certain conditions of Medtronic’s PMA approval of the Implantable System for Remodulin must be satisfied prior to launch or sale of the Implantable System for Remodulin; accordingly, Implantable System for Remodulin labeling may be revised in the process of satisfying such conditions of approval.

Prefilled, pre-programmed, single-use PatchPump® for subcutaneous administration of treprostinil.

Dry Powder Inhaled (DPI) treprostinil in a small handheld device for the treatment of pulmonary arterial hypertension (PAH).

Next-generation ambulatory micro-infusion pumps with smartphone compatibility.

Oral prodrug being developed to provide increased tolerability and convenience through a once-daily dosing regimen.

Prodrug of treprostinil that is being developed to reduce site pain associated with subcutaneous delivery of treprostinil.

An IP receptor agonist that is a next-generation, once-a-day oral therapy that targets the prostacyclin pathway for patients with pulmonary arterial hypertension (PAH).

Phase 2 clinical trial to establish the efficacy and safety of repeat dosing of autologous endothelial progenitor cells (EPCs) transfected with human endothelial nitric oxide synthase (eNOS) and expanded ex-vivo in patients with PAH on top of conventional treatments.

Enhanced Mesenchymal stem cells for the treatment of sepsis and pulmonary arterial hypertension (PAH).